Buscador de publicacions

Publicacions

  • Muñoz JP, Cristina Larrosa Espinosa, Chamorro S, Pérez-Jaume S, Simao M, Sanchez-Sierra N, Varo A, Gorostegui-Obanos M, Castañeda-Heredia A, Garraus-Oneca M, Lopez-Miralles S and Mora J.

    Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes

    Cancers . 15(19): . Nº de cites: 2

    [doi:10.3390/cancers15194837]

  • Gomez-Gonzalez S, Llano J, Garcia-López M, Garrido- García A, Suñol M, Lemos I, Pérez-Jaume S, Salvador-Marcos N, Gene-Olaciregui N, Galán RA, Santa-María López V, Pérez-Somarriba M, Castañeda-Heredia A, Hinojosa J, Winter U, Moreira FB, Lubieniecki F, Vazquez V, Mora J, Cruz-Martínez O, Morales-La Madrid A, Perera A and Lavarino C.

    EpiGe: A machine-learning strategy for rapid classification of medulloblastoma using PCR-based methyl-genotyping

    iScience . 26(9): 107598-107598.

    [doi:10.1016/j.isci.2023.107598]

  • Varo A, Castañeda-Heredia A, Chamorro S, Muñoz JP, Gorostegui-Obanos M, Celma MS, Lopez S, Simao M, Pérez-Jaume S and Mora J.

    Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab

    Frontiers in oncology . 13: 1164949-1164949. Nº de cites: 3

    [doi:10.3389/fonc.2023.1164949]

  • Mora J, Castañeda-Heredia A, Gorostegui-Obanos M, Varo A, Pérez-Jaume S, Simao M, Muñoz JP, Garraus-Oneca M, Cristina Larrosa Espinosa, Salvador-Marcos N, Lavarino C, Krauel L and Mañe S.

    Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report

    Cancers . 15(9): . Nº de cites: 3

    [doi:10.3390/cancers15092535]

  • Gargallo P, Bautista F, Juan-Ribelles A, Izquierdo E, Soriano A, de Rojas T, Escudero A, Lavarino C, Solano P, Hladun R, Rubio-San-Simón A, Martínez-Romera I, Calabria I, Gene-Olaciregui N, Castañeda-Heredia A, de Álava E, Pérez-Martínez A, Astigarraga I, Patiño-García A, Alonso J, Fernández-Teijeiro A, Cañete A and Moreno L.

    Current status of precision medicine in pediatric oncology in Spain: a consensus report by the Spanish Society of Paediatric Haematology and Oncology (SEHOP)

    CLINICAL & TRANSLATIONAL ONCOLOGY . 24(5): 809-815. Nº de cites: 1

    [doi:10.1007/s12094-021-02759-7]

  • Castañeda-Heredia A, Gorostegui-Obanos M, Miralles SL, ALICIA CHAMIZO BREMER, Patiño SC, Flores MA, Garraus-Oneca M, Lazaro JJ, Santa-María López V, Varo A, Muñoz JP and Mora J.

    How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Deu in Barcelona, Spain

    ESMO Open . 7(2): 100462-100462. Nº de cites: 6

    [doi:10.1016/j.esmoop.2022.100462]

  • Rubio-San-Simón A, Hladun Alvaro R, Juan Ribelles A, Castañeda-Heredia A, Guerra-García P, Verdú-Amorós J, Andrés M, Cañete A, Rives-Solà S, Pérez-Martínez A, Mora J, Patiño-García A, Lassaleta A, Llort A, Ramírez M, Mata C, Gallego S, Martín-Broto J, Cruz-Martínez O, Morales-La Madrid A, Solano P, Martínez Romera I, Fernández-Teijeiro A, Bautista F and Moreno L.

    The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP)

    CLINICAL & TRANSLATIONAL ONCOLOGY . 23(12): 2489-2496. Nº de cites: 2

    [doi:10.1007/s12094-021-02649-y]

  • Mora J, Castañeda-Heredia A, Gorostegui M, Santa-María V, Garraus-Oneca M, Muñoz JP, Varo A, Pérez-Jaume S and Mañe S.

    Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission

    PEDIATRIC BLOOD & CANCER . 68(10): 29121. Nº de cites: 19

    [doi:10.1002/pbc.29121]

  • Castillo H, Pascual-Pastó G, Pérez-Jaume S, Resa-Parés C, Vilà-Ubach M, Monterrubio C, Jimenez-Cabaco A, Baulenas-Farrés M, Muñoz-Aznar O, Salvador-Marcos N, Cuadrado-Vilanova M, Gene-Olaciregui N, Balaguer-Lluna L, Burgeño-Sandoval V, Vicario FJ, Manzanares-Quintela A, Castañeda-Heredia A, Santa-María López V, Cruz-Martínez O, Celis-Passini V, Morales-La Madrid A, Garraus-Oneca M, Gorostegui M, Vancells M, Carrasco-Torrents R, Krauel L, Torner-Rubies F, Suñol M, Lavarino C, Mora J and Carcaboso AM.

    Prognostic value of patient-derived xenograft engraftment in pediatric sarcomas

    JOURNAL OF PATHOLOGY CLINICAL RESEARCH . 7(4): 338-349. Nº de cites: 11

    [doi:10.1002/cjp2.210]

  • Mora J, Castañeda-Heredia A, Colombo MC, Gorostegui M, Fernando Gómez Muñoz, Mañe S, Santa-María López V, Garraus-Oneca M, Macias N, Pérez-Jaume S, Muñoz-Aznar O, Muñoz JP, Barber-Martínez de la Torre I and Suñol M.

    Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma

    Cancers . 13(6): 164. Nº de cites: 7

    [doi:10.3390/cancers13061264]